Transvenous phrenic nerve stimulation, a novel therapeutic approach for central sleep apnea

Ding, Ning; Zhang, Xilong

doi:10.21037/jtd.2018.03.59

Cited by 15 publications

(7 citation statements)

References 24 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Periodic breathing with CSA is common in HF and is associated with poor QoL and increased risk of morbidity and mortality [176]. Adaptive servo-ventilation had no significant effect on the primary end point in patients who had HFrEF and predominantly CSA, but all-cause and cardiovascular mortality were both increased with this therapy, as seen in results from SERVE-HF [177].…”

Section: Central Sleep Apnoea (Csa)mentioning

confidence: 88%

Reappraisal on pharmacological and mechanical treatments of heart failure

Liang

Zhao

Zhang

et al. 2020

Cardiovasc Diabetol

View full text Add to dashboard Cite

Heart failure (HF) is a highly frequent disorder with considerable morbidity, hospitalization, and mortality; thus, it invariably places pressure on clinical and public health systems in the modern world. There have been notable advances in the definition, diagnosis, and treatment of HF, and newly developed agents and devices have been widely adopted in clinical practice. Here, this review first summarizes the current emerging therapeutic agents, including pharmacotherapy, device-based therapy, and the treatment of some common comorbidities, to improve the prognosis of HF patients. Then, we discuss and point out the commonalities and areas for improvement in current clinical studies of HF. Finally, we highlight the gaps in HF research. We are looking forward to a bright future with reduced morbidity and mortality from HF.

show abstract

Section: Central Sleep Apnoea (Csa)mentioning

confidence: 88%

Reappraisal on pharmacological and mechanical treatments of heart failure

Liang

Zhao

Zhang

et al. 2020

Cardiovasc Diabetol

View full text Add to dashboard Cite

show abstract

“…These include theophylline, acetazolamide, oxygen and CPAP/BIPAP, some of which showed arrhythmogenic potential that could lead to cardiac arrhythmias. 67,68,70 An alternative approach to treat moderate to severe CSA in HFrEF is a fully implantable neurostimulation system (remedē System, Respicardia, Inc.). 71 It stimulates the phrenic nerve to move the diaphragm causing inspiration by activating the diaphragm to generate negative pressure in the chest (similar to A,B) Implantable pulse generator that connects to the heart with standard pacing leads and delivers BackBeat CNT to lower blood pressure.…”

Section: Phrenic Nerve Stimulation For Central Sleep Apnoeamentioning

confidence: 99%

“…There are few other treatment options for CSA, with limited randomized data supporting those options. These include theophylline, acetazolamide, oxygen and CPAP/BIPAP, some of which showed arrhythmogenic potential that could lead to cardiac arrhythmias 67,68,70 …”

Section: Phrenic Nerve Stimulation For Central Sleep Apnoeamentioning

confidence: 99%

Extra‐cardiac targets in the management of cardiometabolic disease: Device‐based therapies

et al. 2021

View full text Add to dashboard Cite

Heart failure (HF) does not occur in a vacuum and is commonly defined and exacerbated by its co-morbid conditions. Neurohormonal imbalance and systemic inflammation are some of the key pathomechanisms of HF but also commonly encountered co-morbidities such as arterial hypertension, diabetes mellitus, cachexia, obesity and sleep-disordered breathing. A cornerstone of HF management is neurohormonal blockade, which in HF with reduced ejection fraction has been tied to a reduction in morbidity and mortality. Pharmacological treatment effective in patients with HF with reduced ejection fraction did not show substantial effects in HF with preserved ejection fraction. Here, we review novel device-based therapies using neuromodulation of extra-cardiac targets to treat cardiometabolic disease.

show abstract

“…These findings were similar to previously reported CPAP effects on moderate-to-severe OSA (Schwartz et al, 2012). Implantable therapy also exists for treatment of CSA, which includes transvenous phrenic nerve stimulation therapy (Ding & Zhang, 2018).…”

Section: Treatment Of Obstructive Sleep Apneamentioning

confidence: 99%

Diagnosis and treatment of obstructive sleep apnea and its impact on cardiovascular disease

Maher

Coke

2021

J Am Assoc Nurse Pract

View full text Add to dashboard Cite

Obstructive sleep apnea (OSA) is a prevalent disorder that has direct correlation to cardiovascular disease. Understanding the etiology and symptoms of this condition as it relates to cardiovascular disease can improve comprehensive health assessments and determine the use of appropriate screening tools. This case-based approach follows a patient through assessment, diagnosis, and treatment options. Although lifestyle behavior changes are recommended for all patients, other options, such as positive airway pressure therapy, oral appliances, implantable therapy, surgery, and pharmacological and oxygen therapies, exist and should be explored as treatment options. Yearly follow-up provides the best method for long-term treatment success. Treatment of OSA reduces the incidence of cardiac comorbidities and improves cardiovascular health.

show abstract

Transvenous phrenic nerve stimulation, a novel therapeutic approach for central sleep apnea

Cited by 15 publications

References 24 publications

Reappraisal on pharmacological and mechanical treatments of heart failure

Reappraisal on pharmacological and mechanical treatments of heart failure

Extra‐cardiac targets in the management of cardiometabolic disease: Device‐based therapies

Diagnosis and treatment of obstructive sleep apnea and its impact on cardiovascular disease

Contact Info

Product

Resources

About